Back

Relation of Nonsteroidal Anti-Inflammatory Drugs and Time in Therapeutic Range in Bleeding Risk in Atrial Fibrillation: the SPORTIF Trials

19 March 2018 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Managing the thromboembolic risk in atrial fibrillation Atrial Fibrillation - Stroke Prevention - Oral Anticoagulation EHRA Premium Access EHRA 2018

About the speaker

Photo
Associate Professor Marco Proietti

University of Milan, Milan (Italy)

6 More presentations in this session

Presentation thumbnail
Incidence of atrial arrhythmia and uptake of anticoagulation in stroke and non-stroke populations according to arrhythmia burden; a 7-year experience.
Doctor P. Chousou (Cambridge, GB)
Abstract Slides
Presentation thumbnail
Incidence and predictors of left atrial appendage thrombus in patients treated with direct oral anticoagulants versus warfarin for non-valvular atrial fibrillation
Doctor K. Minami (Utsunomiya, JP)
Abstract Slides
Presentation thumbnail
Left atrial stunning as a predictor of atrial fibrillation occurrence after cryptogenic stroke
Doctor J. Farinha (Setubal, PT)
Abstract Slides
Presentation thumbnail
Indications for and outcome in patients undergoing left atrial appendage closure - Results of the Austrian LAAC Registry
Mr D. Zweiker (Vienna, AT)
Abstract Slides
Presentation thumbnail
Differences in anticoagulation strategy and outcome in patients with atrial fibrillation according to renal function

Access the full session

Session thumbnail
Managing the thromboembolic risk in atrial fibrillation

The Event

Event poster

EHRA 2018

19 March 2018 15:35 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources